Hereditary Hemorrhagic Telangiectasia
Hematology·MeSH: Telangiectasia, Hereditary Hemorrhagic
Prevalence
30.0 / 100K
2 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| ALN-6400 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) |
Preclinical(1)
| Drug | Company |
|---|---|
| tx2100 | Tectonic Therapeutic, Inc. (TECX) |
Compare drugs
Frequently asked questions
How many drugs are in development for Hereditary Hemorrhagic Telangiectasia?
BioSniper tracks 2 drugs in development for Hereditary Hemorrhagic Telangiectasia across 2 companies.
How many clinical trials target Hereditary Hemorrhagic Telangiectasia?
There are 1 clinical trial targeting Hereditary Hemorrhagic Telangiectasia tracked by BioSniper.
What is the prevalence of Hereditary Hemorrhagic Telangiectasia?
The estimated prevalence of Hereditary Hemorrhagic Telangiectasia is approximately 30.0 per 100,000 population.
Deep-dive into Hereditary Hemorrhagic Telangiectasia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis